PA8586201A1 - Nuevas formulaciones de liberacion prolongada inyectables - Google Patents

Nuevas formulaciones de liberacion prolongada inyectables

Info

Publication number
PA8586201A1
PA8586201A1 PA20038586201A PA8586201A PA8586201A1 PA 8586201 A1 PA8586201 A1 PA 8586201A1 PA 20038586201 A PA20038586201 A PA 20038586201A PA 8586201 A PA8586201 A PA 8586201A PA 8586201 A1 PA8586201 A1 PA 8586201A1
Authority
PA
Panama
Prior art keywords
prolonged release
release formulations
new injectable
injectable prolonged
new
Prior art date
Application number
PA20038586201A
Other languages
English (en)
Spanish (es)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8586201A1 publication Critical patent/PA8586201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
PA20038586201A 2002-10-25 2003-10-14 Nuevas formulaciones de liberacion prolongada inyectables PA8586201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
PA8586201A1 true PA8586201A1 (es) 2004-09-16

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038586201A PA8586201A1 (es) 2002-10-25 2003-10-14 Nuevas formulaciones de liberacion prolongada inyectables

Country Status (20)

Country Link
US (1) US20040138237A1 (enExample)
EP (1) EP1575616A2 (enExample)
JP (1) JP2006514923A (enExample)
KR (1) KR20050055781A (enExample)
CN (1) CN1849110A (enExample)
AR (1) AR041722A1 (enExample)
AU (1) AU2003267788A1 (enExample)
BR (1) BR0315568A (enExample)
CA (1) CA2503076A1 (enExample)
MX (1) MXPA05002561A (enExample)
NL (1) NL1024590C2 (enExample)
NO (1) NO20052463L (enExample)
PA (1) PA8586201A1 (enExample)
PE (1) PE20040499A1 (enExample)
PL (1) PL377679A1 (enExample)
RU (1) RU2310450C2 (enExample)
TW (1) TW200423941A (enExample)
UY (1) UY28038A1 (enExample)
WO (1) WO2004037289A2 (enExample)
ZA (1) ZA200501921B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
KR20070119678A (ko) * 2005-04-13 2007-12-20 화이자 프로덕츠 인코포레이티드 지속 방출되는 나노입자 조성물을 제공하기 위한주사가능한 저장소 제제 및 방법
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
JP5643195B2 (ja) * 2008-06-16 2014-12-17 デビオファーム インターナショナル ソシエテ アノニム 濃縮オキサリプラチン溶液及びその調製方法
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
JP7258561B2 (ja) 2016-07-06 2023-04-17 オリエント ファーマ シーオー．，エルティーディー． 薬物組成物、バリヤー層及び薬物層を有している経口投与形態
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2328197C (en) * 1998-04-14 2007-11-20 The General Hospital Corporation Methods for treating neuropsychiatric disorders
EE04704B1 (et) * 1999-05-27 2006-10-16 Pfizer Products Inc. Ziprasidooni suspensioon
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
CA2441744C (en) * 2001-03-20 2011-07-12 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
CA2503076A1 (en) 2004-05-06
KR20050055781A (ko) 2005-06-13
TW200423941A (en) 2004-11-16
JP2006514923A (ja) 2006-05-18
RU2005112207A (ru) 2005-09-10
RU2310450C2 (ru) 2007-11-20
WO2004037289A2 (en) 2004-05-06
NL1024590A1 (nl) 2004-04-27
AU2003267788A1 (en) 2004-05-13
BR0315568A (pt) 2005-08-23
PE20040499A1 (es) 2004-08-18
PL377679A1 (pl) 2006-02-06
US20040138237A1 (en) 2004-07-15
AR041722A1 (es) 2005-05-26
UY28038A1 (es) 2004-05-31
NO20052463L (no) 2005-05-23
ZA200501921B (en) 2006-10-25
WO2004037289A3 (en) 2005-12-01
CN1849110A (zh) 2006-10-18
NL1024590C2 (nl) 2005-05-23
MXPA05002561A (es) 2005-05-05
EP1575616A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
UY28662A1 (es) Agente endoparasiticida para administracion topica
BRPI0409516A (pt) composição, uso de uma composição e processo de melhora da penetração de um ativo farmacêutico
AR047928A1 (es) Derivados de tetrahidropiridoindol
ECSP056071A (es) Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
AR109263A2 (es) Composición que comprende moxidectina
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR041826A1 (es) Formulaciones de liberacion prolongada en formas de suspension
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
TW200509863A (en) Irradiation device for medical use
BRPI0511389A (pt) composição e seu uso
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
UY28537A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
HN2003000104A (es) Derivados de ciclopenteno
ES2325291A1 (es) "uso de un extracto de silybum marianum"
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
AR022955A1 (es) Solucion de ibuprofen